Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be giving an oral presentation at the upcoming AD/PD, Alzheimer’s & Parkinson’s Diseases Conference scheduled to be held in Barcelona, Spain this March 15-20th, 2022.
Inhibikase is focused on developing therapeutics to modify the course of Parkinson’s disease and related disorders.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics for Parkinson’s disease and other related disorders. The company’s multi-therapeutic pipeline focuses on neurodegeneration.
Inhibikase’s lead program IkT-148009 is an Abelson Tyrosine Kinase (c-Abl) inhibitor designed to target the treatment of Parkinson’s disease both inside and outside the brain.
The company’s multi-therapeutic pipeline is currently pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, or MSA, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Inhibikase HQ in Atlanta, Georgia with additional offices in Boston, Massachusetts.
Inhibikase’s Drug Innovation Engine RAMP (Re-engineering Approach with Metabolism Preserved) drug innovation engine enables the company to design and develop novel small-molecule product candidates for the treatment of neurodegenerative diseases that feature enhanced potency and preserved safety profile.
About Parkinson’s Disease
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that affects one in 500 people, or about one million Americans. The disease is caused by the death of dopamine-secreting neurons in the brain and leads to a wide range of debilitating motor symptoms, including trembling hands, rigidity, slowed movements and unsteady balance.
The disease also affects non-motor functions, including sleep, mood and cognition. Parkinson’s disease progresses over time and can eventually lead to complete disability and premature death. There is no known cure for Parkinson’s disease and available treatments only address symptoms, not the underlying cause of the disease.
Currently the approved marketed therapeutic approaches to treat Parkinson’s help manage the symptoms of the disease, but there are no treatments available designed to slow or stop the disease’s relentless progression. The underlying causes of neural death in Parkinson’s disease are only beginning to be understood.
IkT-148009 for Parkinson’s Disease
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication that is engineered and designed to be a once-daily, chronically administered oral medication that targets an underlying biological mechanism that is believed to lead to Parkinson’s disease. The goal of IkT-148009 is to halt disease progression along with reversing functional loss.
Inhibikase’s AD/PD, Alzheimer’s & Parkinson’s Diseases Conference Presentation
At the 2022 AD/PD, Alzheimer’s & Parkinson’s Diseases Conference in Barcelona Dr. Werner will be discussing the preclinical results from Phase 1and Phase 1b studies of the company’s highly selective Abelson Tyrosine Kinase inhibitor IkT-148009 developed for the treatment of Parkinson’s disease.
In preclinical animal models, IkT-148009 demonstrated the ability to clear alpha-synuclein aggregates from the brain and GI tract along with protecting neurons from degeneration as well as the potential to promote regeneration of neurons, and induce substantial functional recovery in motor and non-motor function measures.
Presentation Title: Parkinson’s Disease Modification Through Abl Kinase Inhibition by Dr. Milton Werner Ph.D., CEO of Inhibikase Therapeutics
Date: Friday, March 18, 2022
Time: 5:45 PM – 6:00 PM
IkT-148009 Phase 1/1b Study Information
The Phase 1 study was initiated in February 2021 and demonstrated high levels of drug exposure in the blood with no clinically significant adverse events observed across 88 subjects in single and/or 7-day dosing up to 250 mg. Penetration into the central nervous system was confirmed by measures of IkT-148009 in the spinal fluid.
In the ongoing Phase 1b study in mild to moderately advanced Parkinson’s patients (Hoehn & Yahr scale ≤ 3.0), no clinically meaningful adverse events have been observed and Inhibikase will provide an update on safety and pharmacokinetics of IkT-148009 in patients.
The promising results of the Phase 1 and Phase 1b study continue to validate the safety and therapeutic potential of IkT-148009 as a potential disease-modifying treatment for Parkinson’s disease. Inhibikase expects to initiate a Phase 2 study for IkT-148009 in the second quarter of 2022.
